Spondyloarthritis & psoriatic arthritis
Treat-to-target in real-life psoriatic arthritis patients: achieving minimal disease activity with bDMARDs/tsDMARDs and potential barriers
Authors' conclusion
MDA is an attainable target in real-life. AxPsA represents a difficult-to-treat subset. Sustained MDA depends on disease features (axPsA) as well as patients' characteristics (e.g. age, bDMARDs/tDMARDs duration, comorbidities).
Study context
- Population
- Consecutive psoriatic arthritis (PsA) patients on stable bDMARDs/tsDMARDs, evaluated every 6 months up to 36 months52% axPsA
- Participants
- 104 patients
- Exposure
- Patients achieving sustained minimal disease activity (MDA) vs those who did not
- Outcome
- Frequency of MDA
- Follow-up
- Every 6 months, up to 36 months
Methodological detailsreal-life, single-centre, longitudinal, multivariable generalized estimating equation (GEE) models
- Real-life
- Single-centre
- Longitudinal
- Multivariable GEE models
Main finding
As reported in the abstract
MDA across all evaluations
Reached MDA across all evaluations
52-61%
Observational data: associations, not effects.
Further findings
Independent predictors of MDA (GEE)
- Age, Beta
- −0.05
- bDMARDs/tsDMARDs duration, Beta
- +0.31
- axPsA, Beta
- −1.07
- FM, Beta
- −3.35
- Osteoarthritis (OA), Beta
- −1.87
- BMI≥35, Beta
- −2.53
Ankylosing spondylitis disease activity score-LDA (ASDAS-LDA) in axPsA
- Achieved ASDAS-LDA across all evaluations
- 17-24%
Independent predictors of ASDAS-LDA (GEE)
- Age, Beta
- −0.01
- FM, Beta
- −2.03
- OA, Beta
- −1.30
Characteristics in sustained MDA
- AxPsA, FM, OA and BMI≥35 less frequent in patients with sustained MDA
Original publication
Treat-to-target in real-life psoriatic arthritis patients: achieving minimal disease activity with bDMARDs/tsDMARDs and potential barriers. Semin Arthritis Rheum. Published 4 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →